{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-309853","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2025-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.563236+00:00","generated_at":"2026-05-16T14:14:05.703084+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"TuHURA draws additional $1.5M under amended loan; total $3M, issues warrants","bullets":["Borrowed an additional $1.5M on Dec 2, 2025, bringing aggregate loans to $3.0M under the Loan Agreement.","Amendment extends availability period to Dec 5, 2025 and sets warrants at 150K shares per $1.5M borrowed.","Issued warrant to purchase 234,783 shares at $1.81/share, expiring in two years.","Lender is Matthew Nachtrab Revocable Trust; warrants cover both the initial and second loan advances."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-309853","json":"https://secwatch.observer/filing/0001193125-25-309853.json","markdown":"https://secwatch.observer/filing/0001193125-25-309853.md","text":"https://secwatch.observer/filing/0001193125-25-309853.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000119312525309853/0001193125-25-309853-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000119312525309853/hura-20251202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T14:14:05.703084+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1db4023745ee145add526e137a0748e9767a28ad","claim":"TuHURA Biosciences, Inc./NV incurred loan of $1.5 million with Matthew Nachtrab Revocable Trust dated 12/18/2014.","evidence_excerpt":"the Company borrowed an additional $1.5 million from the Lender under the Loan Agreement (the “Second Loan”), which resulted in aggregate Loans of $3.0 million made to the Company under the Loan Agreement.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1498382/000119312525309853/0001193125-25-309853-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$1.5 million"},{"label":"Counterparty","value":"Matthew Nachtrab Revocable Trust dated 12/18/2014"},{"label":"Event","value":"incurrence"}]},{"claim_id":"64eabb7c28a4b060b5d40a7dee93fb024ad59d03","claim":"TuHURA Biosciences, Inc./NV amended loan with Matthew Nachtrab Revocable Trust dated 12/18/2014.","evidence_excerpt":"(the “Company”) on October 31, 2025, the Company previously entered into a Secured Promissory Note and Loan Agreement, dated October 27, 2025 (the “Loan Agreement”), with the Matthew Nachtrab Revocable Trust dated 12/18/2014 (the “Lender”). Pursuant to the terms of the Loan Agreement, the Lender agreed to make loans to the Company in an aggregate principal amount of up to $3.0 million (the “Loans”) during a 30-day availability period beginning on the date of the Loan Agreement (the “Availability Period”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1498382/000119312525309853/0001193125-25-309853-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Counterparty","value":"Matthew Nachtrab Revocable Trust dated 12/18/2014"},{"label":"Event","value":"amendment"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}